Tags

Type your tag names separated by a space and hit enter

Committee Opinion no. 514: emergent therapy for acute-onset, severe hypertension with preeclampsia or eclampsia.
Obstet Gynecol. 2011 Dec; 118(6):1465-1468.OG

Abstract

Acute-onset, persistent (lasting 15 minutes or more), severe systolic (greater than or equal to 160 mm Hg) or severe diastolic hypertension (greater than or equal to 110 mm Hg) or both in pregnant or postpartum women with preeclampsia or eclampsia constitutes a hypertensive emergency. Severe systolic hypertension may be the most important predictor of cerebral hemorrhage and infarction in these patients and if not treated expeditiously can result in maternal death. Intravenous labetalol and hydralazine are both considered first-line drugs for the management of acute, severe hypertension in this clinical setting. Close maternal and fetal monitoring by the physician and nursing staff are advised. Order sets for the use of labetalol and hydralazine for the initial management of acute, severe hypertension in pregnant or postpartum women with preeclampsia or eclampsia have been developed.

Pub Type(s)

Journal Article
Practice Guideline

Language

eng

PubMed ID

22105295

Citation

"Committee Opinion No. 514: Emergent Therapy for Acute-onset, Severe Hypertension With Preeclampsia or Eclampsia." Obstetrics and Gynecology, vol. 118, no. 6, 2011, pp. 1465-1468.
Committee Opinion no. 514: emergent therapy for acute-onset, severe hypertension with preeclampsia or eclampsia. Obstet Gynecol. 2011;118(6):1465-1468.
(2011). Committee Opinion no. 514: emergent therapy for acute-onset, severe hypertension with preeclampsia or eclampsia. Obstetrics and Gynecology, 118(6), 1465-1468. https://doi.org/10.1097/AOG.0b013e31823ed1ef
Committee Opinion No. 514: Emergent Therapy for Acute-onset, Severe Hypertension With Preeclampsia or Eclampsia. Obstet Gynecol. 2011;118(6):1465-1468. PubMed PMID: 22105295.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Committee Opinion no. 514: emergent therapy for acute-onset, severe hypertension with preeclampsia or eclampsia. PY - 2011/11/23/entrez PY - 2011/11/23/pubmed PY - 2012/9/14/medline SP - 1465 EP - 1468 JF - Obstetrics and gynecology JO - Obstet Gynecol VL - 118 IS - 6 N2 - Acute-onset, persistent (lasting 15 minutes or more), severe systolic (greater than or equal to 160 mm Hg) or severe diastolic hypertension (greater than or equal to 110 mm Hg) or both in pregnant or postpartum women with preeclampsia or eclampsia constitutes a hypertensive emergency. Severe systolic hypertension may be the most important predictor of cerebral hemorrhage and infarction in these patients and if not treated expeditiously can result in maternal death. Intravenous labetalol and hydralazine are both considered first-line drugs for the management of acute, severe hypertension in this clinical setting. Close maternal and fetal monitoring by the physician and nursing staff are advised. Order sets for the use of labetalol and hydralazine for the initial management of acute, severe hypertension in pregnant or postpartum women with preeclampsia or eclampsia have been developed. SN - 1873-233X UR - https://www.unboundmedicine.com/medline/citation/22105295/Committee_Opinion_no__514:_emergent_therapy_for_acute_onset_severe_hypertension_with_preeclampsia_or_eclampsia_ L2 - https://doi.org/10.1097/AOG.0b013e31823ed1ef DB - PRIME DP - Unbound Medicine ER -